Bio-Path Holdings, Inc.

Bio-Path reported Q3 2024 net loss of $2.1 million, or $0.70 per share, versus a net loss of $3.2 million, or $0.36 per share, in Q3 2023. R&D expense fell to $1.3 million from $2.3 million, mainly from lower manufacturing and AML trial spending, while G&A rose to $1.3 million from $1.0 million due to legal fees and salaries/benefits. Cash was $0.6 million at September 30, 2024, versus $1.1 million at December 31, 2023; operating cash use for the first nine months was $7.7 million versus $9.7 million a year ago, and financing provided $7.2 million. No formal revenue, gross margin, or forward revenue guidance was given, and management instead pointed to continued clinical progress, obesity preclinical studies starting this quarter, and a potential BP1001-A solid tumor data readout early next year.

Peter Nielsen framed the quarter as a step forward in broadening Bio-Path’s DNAbilize platform, emphasizing the company’s entry into obesity and metabolic disease with BP1001-A. He also highlighted continued advancement across the oncology pipeline, including AML and solid tumor studies, and said the company is ‘setting the stage for a strong finish to the year.’ His tone was optimistic and development-focused, with repeated emphasis on platform potential and the company’s mission to create value for patients and stakeholders.

Anthony Price said the quarter’s net loss improved to $2.1 million from $3.2 million a year earlier, and R&D spending declined to $1.3 million from $2.3 million due to lower manufacturing and clinical trial expense timing. He noted G&A increased to $1.3 million from $1.0 million because of legal fees and compensation-related costs. Cash ended at just $0.6 million, and operating cash burn for the first nine months was $7.7 million, partially offset by $7.2 million of financing cash inflow.

There was no substantive analyst Q&A in the transcript; the operator opened the question session, but no questions were asked before it concluded. As a result, there were no additional management clarifications on financing, timelines, or clinical data beyond the prepared remarks.